Initiator Pharma A/S secures bridge financing in preparation of a clinical phase 2a trial for the candidate drug IP2018
(WorldNews Denmark)

Initiator Pharma A/S (`Initiator Pharma`) is currently conducting a clinical phase 2a trial for the company`s main candidate IPED2015, which is intended to be completed later in the summer. Initiator Pharma is now able to announce that the company has secured bridge financing of SEK 5 million with the aim pf preparing the company`s other candidate drug IP2018 for the start of a clinical phase 2a trial. With this bridge financing, the company is able to conduct activities for added value before seeking more long-term funding. The clinical phase 2a trial regarding IP2018 is expected to begin in early 2020. IP2018 - positioning in the market for depression and erectile dysfunction Initiator...